

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Clarus Lifesciences III, L.P.</u> _____ (Last) (First) (Middle) 101 MAIN STREET, SUITE 1210 _____ (Street) CAMBRIDGE MA 02142 _____ (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>AVROBIO, Inc. [ AVRO ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 06/25/2018	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	06/25/2018		C		2,283,434	A	(1)	2,283,434	I	See Footnote <sup>(2)</sup>
Common Stock	06/25/2018		C		678,891	A	(3)	2,962,325	I	See Footnote <sup>(2)</sup>

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Series A Preferred Stock	(3)	06/25/2018		C		9,435,150		(4)	(4)	Common Stock	2,283,434 <sup>(4)</sup>	\$0.00	0	I	See footnote <sup>(2)</sup>
Series B Preferred Stock	(3)	06/25/2018		C		2,805,179		(4)	(4)	Common Stock	678,891 <sup>(4)</sup>	\$0.00	0	I	See footnote <sup>(2)</sup>

1. Name and Address of Reporting Person\*  
Clarus Lifesciences III, L.P.  
 \_\_\_\_\_  
 (Last) (First) (Middle)  
 101 MAIN STREET, SUITE 1210  
 \_\_\_\_\_  
 (Street)  
 CAMBRIDGE MA 02142  
 \_\_\_\_\_  
 (City) (State) (Zip)

1. Name and Address of Reporting Person\*  
Clarus Ventures III GP, L.P.  
 \_\_\_\_\_  
 (Last) (First) (Middle)  
 101 MAIN STREET, SUITE 1210  
 \_\_\_\_\_  
 (Street)  
 CAMBRIDGE MA 02142  
 \_\_\_\_\_  
 (City) (State) (Zip)

1. Name and Address of Reporting Person\*  
Clarus Ventures III, LLC  
 \_\_\_\_\_  
 (Last) (First) (Middle)  
 101 MAIN STREET, SUITE 1210  
 \_\_\_\_\_  
 (Street)  
 CAMBRIDGE MA 02142  
 \_\_\_\_\_  
 (City) (State) (Zip)

(Street)	CAMBRIDGE	MA	02142
(City)		(State)	(Zip)

**Explanation of Responses:**

1. Represents the total number of shares of Common Stock received by Clarus Lifesciences III, L.P. ("Clarus") upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering.
2. The shares are held directly by Clarus. The general partner of Clarus is Clarus Ventures III GP, L.P. ("GPLP"). Clarus Ventures III, LLC, ("LLC") is the general partner of GPLP. Each of Nicholas Galakatos, Dennis Henner, Robert Liptak, Scott Requadt, Nicholas Simon, and Kurt Wheeler, as individual managing directors of the LLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Each of Messrs. Galakatos, Henner, Liptak, Requadt, Simon and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which he does not have an actual pecuniary interest. Scott G. Requadt is a member of LLC and a member of the Issuer's board of directors. Mr. Requadt disclaims beneficial ownership of such shares, except to the extent of his proportionate pecuniary interest therein, if any.
3. Represents the total number of shares of Common Stock received by Clarus upon the conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering.
4. All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date.

**Remarks:**

Clarus Lifesciences III, L.P., By:  
its General Partner, Clarus  
Ventures III GP, L.P., By: its  
General Partner, Clarus Ventures III, LLC, By: Robert Liptak,  
Managing Director, /s/ Robert  
Liptak      06/25/2018

Clarus Ventures III GP, L.P., By:  
its General Partner, Clarus  
Ventures III, LLC, By: Robert  
Liptak, Managing Director, /s/  
Robert Liptak      06/25/2018

Clarus Ventures III, LLC, By:  
Robert Liptak, Managing  
Director, /s/ Robert Liptak      06/25/2018

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**